Oligodendrocyte progenitor cell compositions
Compositions comprising a population of oligodendrocyte progenitor cells (OPCs), as well as methods of making and using the same, are provided. In one aspect, a container comprising a composition, where the composition comprises a population of cells comprising a plurality of OPCs, and where the population of cells comprises less than 15% undesirable cell types is provided. In another aspect, the population of cells comprises less than 15% undesirable epithelial lineage cells. In yet another aspect, the population of cells comprises less than 2% K7 positive cells. In an aspect, a population of cells comprising a plurality of oligodendrocyte progenitor cells is capable of forming less than one epithelial cyst per 100,000 cells in a cyst assay is provided. An even further aspect of the present disclosure is a container comprising a composition, where the composition comprising a plurality of oligodendrocyte progenitor cells is useful in treating treat stroke, spinal cord injury, and multiple sclerosis.
1. A container comprising a composition, wherein the composition comprises a population of cells comprising a plurality of oligodendrocyte progenitor cells (OPCs), wherein the OPCs express Nestin and one or more markers selected from PDGF-Rα, IGF2, Nkx2.2, Olig1, NG2, Olig2, FABP7, NEUROG2, wherein the population of cells comprises less than 15% undesirable cell types, and wherein the OPCs are the in vitro-derived progeny of expanded but undifferentiated stem cells that were treated with one or more stem cell differentiation modulating molecules selected from a Smoothened agonist or an inhibitor of ALK5, ALK2, or GSK3 prior to differentiation into OPCs.
2. The container according to claim 1 , wherein the undesirable cell types comprise epithelial lineage cells.
3. The container according to claim 2 , wherein the epithelial lineage cells are characterized by the presence of one or more markers selected from the group consisting of: K7 and PCK.
4. The container according to claim 3 , wherein the population of cells comprises less than 2% K7 positive cells.
5. The container according to claim 4 , wherein the population of cells comprises less than 0.2% K7 positive cells.
6. The container according to claim 3 , wherein the population of cells comprises less than 5% PCK positive cells.
7. The container according to claim 1 , wherein the composition comprises at least 1×10 6 cells per milliliter.
8. The container according to claim 1 , wherein the composition has a volume of 20 to 500 microliters.
9. The container of claim 1 , wherein at least 95% of the OPCs express one or more markers selected from PDGF-Rα, IGF2, Nkx2.2, Olig1, and Nestin.
10. The container of claim 1 , wherein at least 95% of the OPCs express Nestin, at least 45% of the OPCs express NG2, and at least 80% of the OPCs express PDGF-Rα.